Hanmi has shown remarkable growth since its foundation in 1973 and has now become the most spotlighted company among Korean pharmaceutical companies. We are proud to be known as a global leader in the quality API production of cephalosporins, cardiovascular, anti-diabetics, gastrointestinal, and CNSs. The facilities have been inspected and approved by UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has been successfully developed and marketed New Combination drug and a series of IMDs with its own patented process, and also succeeded in developing LAPSCOVERY technology, which is enhancing the half-life time for bio-products.

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Primary business activity

Manufacturer/Innovator

Meet us at

CPhI North America 2021

Philadelphia, USA

August 10-12 2021

Book a meeting
View Our Exhibitor Profile

Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information

Address

Telephone

Website

View All Contact Info

Top Products

Adefovir Tab.

Hanmi Pharm. Co. Ltd

Request Info

Alenmax Plus D Tab,

Hanmi Pharm. Co. Ltd

Request Info